gdc
Cancer ResearchClinical TrialsImmunotherapy

Is CAR T-Cell Therapy Safe and Effective?

Claire White discusses the role of the FDA in evaluating new and promising treatments such as CAR T-cell therapy and the complexity of getting approvals.
Video Library – March 6, 2019
Claire White, BSN, RN, CPHON
The Children's Hospital of Philadelphia, Philadelphia, PA
Claire White discusses the role of the FDA in evaluating new and promising treatments such as CAR T-cell therapy and the complexity of getting approvals.
Recommended For You
Breast CancerImmunotherapy
A Breakthrough in the Treatment of Metastatic Triple-Negative Breast Cancer
By Erika Hamilton, MD
Recently, Tecentriq became the first immunotherapy to be approved for the treatment of patients with metastatic triple-negative breast cancer, a particularly difficult type of breast cancer.
Breast CancerImmunotherapy
Keytruda plus Chemotherapy in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive type of cancer that usually has a high rate of disease recurrence (returning) within the first 5 years after diagnosis.
Immunotherapy
Why Target the Immune System?
By Colleen H. Erb, MSN, CRNP, ACNP-BC, AOCNP
The immune system attacks foreign substances by making large numbers of antibodies. These are proteins that attach to a specific protein on the cell called an antigen.
Last modified: September 10, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country